Podcast Summary: Derms on Drugs
Episode: To Scratch or Not to Scratch, That Is the Question
Date: March 14, 2025
Hosts: Matt Zirwas, Laura Ferris, Tim Patton
Guest: Dr. Dan Kaplan (University of Pittsburgh)
Brief Overview
In this lively and insightful episode, the Derms on Drugs team dives deep into the science of itch and scratching—a topic at the very heart of dermatology but, as they show, still full of surprises. They welcome special guest Dr. Dan Kaplan, whose recent paper in Science uncovers new neurological and immunological underpinnings in the infamous itch-scratch cycle. Together, the panel explores why scratching feels so good, how scratching may drive both inflammation and evolutionary advantages, and what this means for conditions like atopic dermatitis. As always, there's plenty of high-level banter and a dash of the show’s signature humor.
Key Discussion Points & Insights
1. The Pleasurability of Scratching (00:13–04:43)
- Matt reviews a landmark fMRI study by Gil Yosipovitch showing that scratching an itch activates brain reward circuits similar to those triggered by sex, gambling, and drugs.
- Only active scratching of one’s own itch (not having someone else do it, or scratching non-itchy skin) produces this intense pleasure.
- Quote: “Active scratching… activates the same parts of your brain as having sex, gambling, using drugs, all these addictive behaviors.” (A, 01:35)
- The panel debates evolutionary reasons for this: is intensive itch relief fundamentally valuable for survival?
2. The Evolutionary Purpose of Itching and Scratching (04:43–06:46)
- Discussion on whether scratching’s main role is to remove parasites (fleas, mites, lice) or something deeper.
- Insight: Scratching may have evolved as a mechanism to get rid of dangerous skin-dwelling parasites, with scabies given as a modern example.
- Quote: “The scratching really does have a benefit to removing mites… scabies. But it’s probably the same for body lice.” (C, 05:44)
3. The Itch-Scratch Cycle and Keratinocyte-Mast Cell Crosstalk (06:53–14:43)
- Tim presents a 2025 JID study on how mechanical stretching of keratinocytes (from scratching) produces reactive oxygen species (ROS), activating mast cells (via TRPA1), releasing tryptase, and further driving itch.
- Summary of experiments: Stretching keratinocytes leads to ROS, which prompts mast cells to degranulate—a core of the itch-scratch cycle in conditions like atopic dermatitis.
- N-acetylcysteine (NAC), an antioxidant, can inhibit this process—aligns with its clinical utility for some skin picking disorders.
- Quote: “The takeaway was—the takeaway. Stretched… keratinocyte supernatant… appeared [to] upregulate TRPA1 expression on mast cells, leading to the release of tryptase…” (D, 08:42)
- Dr. Kaplan highlights the complexity of keratinocyte-derived factors (TSLP, IL-33, ROS), all of which can directly or indirectly worsen itch/inflammation.
- Matt notes this evidence finally made him “buy into” the itch-scratch cycle as a real, propagating force in disease.
4. The Role of Mechanical Stretching in Disease Localization (13:58–15:11)
- Team discusses why psoriasis and atopic dermatitis localize to areas of high skin stretching (elbows, knees).
- Could mechanical stress itself be pro-inflammatory?
5. Neuro-Immune Interactions: Itch, Pain Neurons & Mast Cells (15:33–24:29)
- Dr. Kaplan explains research into how sensory neurons in the skin interact with immune/inflammatory responses.
- Pain-sensing neurons (expressing TRPV1, capsaicin receptor) are key in general inflammation, while itch-specific neurons may be crucial in allergic responses.
- Key Mechanism: Mast cell activation isn’t just via IgE; there’s also the Mrgprx2 receptor. This receptor can be triggered by neuropeptides like substance P (released by neurons), microbial products, and more.
- Quote: “Mast cells released a lot of histamine. But if you look… inside the granules, there’s like, you know, a witch’s brew of different proteases and inflammatory amines… all kinds of things.” (C, 17:17)
- Activation synergy: Simultaneous activation via IgE and Mrgprx2 leads to maximal degranulation/inflammation.
- A pivotal experiment showed that mice unable to scratch (wearing Elizabethan collars) don’t get inflammation even with itch neurons present—implying it’s the act of scratching, not just itch, that triggers the immune cascade.
6. Scratching: Evolutionary Harm and Benefit, Clinical Implications (24:29–30:55)
- Scratching can clearly exacerbate inflammation—explaining chronicity in eczema.
- However, scratching may also protect by reducing bacterial overgrowth (e.g., Staph aureus) as shown in mouse models.
- Quote: “Scratching, while being detrimental, if you have an allergic situation like eczema, is actually beneficial… because it helps reduce the amount of Staph on our skin.” (C, 29:06)
- Debate over whether completely eradicating itch/scratch would harm us—consensus: probably only acutely, e.g., with scabies.
7. Future Therapies and Unanswered Questions (26:51–27:27, 30:25–30:57)
- Multiple companies are developing drugs that block the Mrgprx2 pathway, possibly effective in urticaria or atopic dermatitis.
- The discussion surfaces open questions about which mast cell degranulation pathways drive which diseases, and whether blocking itch could have unintended downsides.
8. Memorable Quotes & Humor
- On study complexity:
“You needed a PhD to fully understand everything. …This is all Cyrus’s fault. He was like, hey, you should do this paper… it was like 47 pages of stuff.” (D, 08:03) - Matt, after changing his mind:
“And son of a bitch, it turns out I was wrong.” (A, 13:43) - Kaplan, on mast cell granules:
“There’s like, you know, a witch’s brew of different proteases and inflammatory amines.” (C, 17:17)
Important Timestamps
| Time | Topic/Quote/Event | |----------|-----------------------------------------------------------------------| | 00:13 | Intro & setup—scratching as pleasure/reward | | 03:19 | Discussion of “active scratching” vs. “passive scratching” | | 06:53 | Patton presents keratinocyte/mast cell-ROS paper | | 10:14 | Kaplan deepens: keratinocyte-derived itch factors | | 11:24 | Matt: This paper finally validates the itch-scratch cycle | | 15:33 | Kaplan explains neuro-immune crosstalk; mast cell biology | | 20:04 | Kaplan: Mouse experiments reveal scratching (not neurons) drive inflammation | | 24:29 | Discussion of scratching as an evolutionary tool (& clinical harm) | | 29:06 | Scratching reduces Staph skin colonization (mice), potential benefit | | 30:25 | Ferris: Does itch/scratch drive bullous pemphigoid? | | 33:13 | Trivia segment on "itch" pop culture (Seven-Year Itch, Cat Scratch Fever) |
Notable Moments & Quotes with Attribution
-
Kaplan on synergistic mast cell activation:
“If you activate both [IgE and Mrgprx2] pathways at the same time, you get this big synergistic response and that’s what’s required for the inflammation.” (C, 23:15) -
Ferris, on reducing itch:
“Do you think there’s any sort of potential harm of, you know, if you could completely knock out itching, do you think that would hurt us?” (B, 30:30) -
Patton’s meta-commentary:
“You really need to make, like, ‘If You Give a Mouse a Cookie,’ but with your research… with little cartoon drawings, and, like, I would have understood this much, much better.” (D, 32:15)
Conclusion
The panel concludes that while scratching can clearly worsen inflammatory disease and drive chronicity (notably in eczema), it may carry surprising short-term antimicrobial benefits—explaining its potent evolutionary reward and persistence as a human behavior. Dr. Kaplan’s research illuminates new cellular pathways (especially the dual-trigger mast cell degranulation) that offer hope for future targeted therapies. The episode blends high-level derma-science with the team’s signature wit, making even immune crosstalk lively and accessible.
For more topics or to submit questions:
Email: questions@dermsondrugs.com
Next episode drops next Friday!
